

Yeow Tee Goh

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5778857/publications.pdf>

Version: 2024-02-01

57
papers

1,115
citations

759233

12
h-index

414414

32
g-index

59
all docs

59
docs citations

59
times ranked

1873
citing authors

#	ARTICLE	IF	CITATIONS
1	Narsoplimab, a Mannan-Binding Lectin-Associated Serine Protease-2 Inhibitor, for the Treatment of Adult Hematopoietic Stem-Cell Transplantation-Associated Thrombotic Microangiopathy. <i>Journal of Clinical Oncology</i> , 2022, 40, 2447-2457.	1.6	36
2	Treatment outcomes of T and natural killer/T-cell lymphoma with ifosfamide, carboplatin and etoposide chemotherapy. <i>Cancer Reports</i> , 2022, , e1552.	1.4	2
3	Thrombocytopenic myelofibrosis (MF) patients previously treated with a JAK inhibitor in a phase 3 randomized study of momelotinib (MMB) versus danazol (DAN) [MOMENTUM].. <i>Journal of Clinical Oncology</i> , 2022, 40, 7061-7061.	1.6	3
4	MOMENTUM: Phase 3 randomized study of momelotinib (MMB) versus danazol (DAN) in symptomatic and anemic myelofibrosis (MF) patients previously treated with a JAK inhibitor.. <i>Journal of Clinical Oncology</i> , 2022, 40, 7002-7002.	1.6	17
5	International consensus statement on the management of cardiovascular risk of Bruton's tyrosine kinase inhibitors in CLL. <i>Blood Advances</i> , 2022, 6, 5516-5525.	5.2	11
6	Newly diagnosed and previously treated multicentric Castleman disease respond equally to siltuximab. <i>British Journal of Haematology</i> , 2021, 192, e28-e31.	2.5	4
7	Second-line bosutinib (BOS) for patients (pts) with chronic phase (CP) chronic myeloid leukemia (CML): Final 10-year results of a phase 1/2 study.. <i>Journal of Clinical Oncology</i> , 2021, 39, 7009-7009.	1.6	4
8	Improved transfusion independence rates for momelotinib versus ruxolitinib in anemic JAKi naïve myelofibrosis patients independent of baseline platelet or transfusion status.. <i>Journal of Clinical Oncology</i> , 2021, 39, e19039-e19039.	1.6	1
9	High-dose methotrexate is effective for prevention of isolated CNS relapse in diffuse large B cell lymphoma. <i>Blood Cancer Journal</i> , 2021, 11, 143.	6.2	17
10	A phase 2 study of carfilzomib, cyclophosphamide and dexamethasone as frontline treatment for transplant-eligible MM with high-risk features (SGH-MM1). <i>Blood Cancer Journal</i> , 2021, 11, 150.	6.2	2
11	DDX3X loss is an adverse prognostic marker in diffuse large B-cell lymphoma and is associated with chemoresistance in aggressive non-Hodgkin lymphoma subtypes. <i>Molecular Cancer</i> , 2021, 20, 134.	19.2	9
12	No association between E3SIT germline mutations and hemophagocytic lymphohistiocytosis in natural killer/T-cell lymphoma. <i>Haematologica</i> , 2021, 106, 1737-1739.	3.5	0
13	Efficacy and Safety of Pegcetacoplan Treatment in Complement-Inhibitor Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria: Results from the Phase 3 Prince Study. <i>Blood</i> , 2021, 138, 606-606.	1.4	9
14	Differential Activation of V Î³4V Î¹ and V Î³9V Î² Cord Blood Derived Gamma Delta T Cells upon Exposure to EBV-Lcl and K562 Cells. <i>Blood</i> , 2021, 138, 2790-2790.	1.4	0
15	Cell-of-origin and bone marrow involvement increase specificity of defining patients with diffuse large B-cell lymphoma at high risk of CNS relapse: a study of 793 patients treated with chemoimmunotherapy in Asia. <i>Leukemia and Lymphoma</i> , 2020, 61, 225-227.	1.3	8
16	Whole-genome sequencing identifies responders to Pembrolizumab in relapse/refractory natural-killer/T cell lymphoma. <i>Leukemia</i> , 2020, 34, 3413-3419.	7.2	42
17	Asciminib, a First-in-Class STAMP Inhibitor, Provides Durable Molecular Response in Patients (pts) with Chronic Myeloid Leukemia (CML) Harboring the T315I Mutation: Primary Efficacy and Safety Results from a Phase 1 Trial. <i>Blood</i> , 2020, 136, 47-50.	1.4	37
18	Bosutinib (BOS) for chronic phase (CP) chronic myeloid leukemia (CML) after imatinib (IMA) failure: 8-y update of a phase I/II study.. <i>Journal of Clinical Oncology</i> , 2020, 38, 7549-7549.	1.6	2

#	ARTICLE	IF	CITATIONS
19	The Asia-Pacific Myeloma and Related Diseases Registry: Preliminary Results of Real-World Treatment Patterns and Clinical Outcomes. <i>Blood</i> , 2020, 136, 30-31.	1.4	0
20	Prognostic Value of Refined Disease Risk Index (rDRI) and Conditioning Regimen in Adult Patients Receiving Unrelated Cord Blood Transplantation (UCBT) for Haematological Malignancies - 15-Year Follow-up of Multicenter Study in Singapore. <i>Blood</i> , 2020, 136, 22-23.	1.4	0
21	Momelotinib's Spleen, Symptom and Anemia Efficacy Is Maintained in Intermediate/High Risk Myelofibrosis Patients with Thrombocytopenia. <i>Blood</i> , 2020, 136, 43-44.	1.4	6
22	Single Cell Immune Profiling Reveals Distinct T Cell Clones and Functional States in in-Vitro Expanded Cord Blood Derived Gamma Delta T Cells. <i>Blood</i> , 2020, 136, 35-36.	1.4	1
23	Phase I/II Dose-Escalation Study of Lenalidomide in Combination with R-GDP for Treatment of Transplant-Ineligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma Followed By Maintenance Lenalidomide. <i>Blood</i> , 2020, 136, 25-26.	1.4	0
24	Inotuzumab ozogamicin versus standard of care in Asian patients with relapsed/refractory acute lymphoblastic leukemia. <i>International Journal of Hematology</i> , 2019, 110, 709-722.	1.6	6
25	Tumor infiltrating lymphocytes from acute myeloid leukemia marrow can be reverted to CD45RA+ central memory state by reactivation in SIP (Simulated Infective Protocol). <i>Immunobiology</i> , 2019, 224, 526-531.	1.9	3
26	Donorâ€¢type fresh frozen plasma is effective in preventing hemolytic reaction in major ABO incompatible allogeneic stem cell transplant. <i>Transfusion</i> , 2019, 59, 335-339.	1.6	6
27	Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial. <i>Lancet, The</i> , 2019, 393, 253-264.	13.7	187
28	The impact of time from diagnosis to treatment in diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2018, 59, 2336-2341.	1.3	12
29	Asciminib, a Specific Allosteric BCR-ABL1 Inhibitor, in Patients with Chronic Myeloid Leukemia Carrying the T315I Mutation in a Phase 1 Trial. <i>Blood</i> , 2018, 132, 792-792.	1.4	8
30	Prognostic Value of the Novel Mucosal Associated Lymphoid Tissue Prognostic Index (MALT-IPI) in Marginal Zone Lymphoma (MZL) Cases. <i>Blood</i> , 2018, 132, 2885-2885.	1.4	0
31	Impact of Incomplete Cycles and Dose Attenuation of Rituximab-Bendamustine on Survival Outcomes in Low-Grade Non-Hodgkin Lymphomas. <i>Blood</i> , 2018, 132, 4165-4165.	1.4	1
32	Overall Survival (OS) Benefit of Oral Ixazomib in Combination with Lenalidomide and Dexamethasone (IRd) Vs Lenalidomide and Dexamethasone (Rd) in Asian Patients (pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM): Pooled-Analysis from the Tourmaline-MM1 and the China Continuation Studies. <i>Blood</i> , 2018, 132, 5637-5637.	1.4	0
33	The Singapore Myeloma Study Group Consensus Guidelines for the management of patients with multiple myeloma. <i>Singapore Medical Journal</i> , 2017, 58, 55-71.	0.6	6
34	Second-Line Bosutinib in Patients with Chronic Phase Chronic Myeloid Leukemia (CP CML) Resistant or Intolerant to Prior Imatinib: An 8-Year Update. <i>Blood</i> , 2017, 130, 900-900.	1.4	9
35	Role of Surveillance Imaging in Patients With Peripheral T-Cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 117-121.	0.4	9
36	A Case of Two Young Brothers with Natural-Killer/T-Cell Lymphoma. <i>Blood</i> , 2016, 128, 5293-5293.	1.4	0

#	ARTICLE	IF	CITATIONS
37	Time from Diagnosis to Initiation of Curative Chemotherapy Affects Outcomes in DLBCL - Data from a Large Asian Cohort. <i>Blood</i> , 2016, 128, 1871-1871.	1.4	0
38	Predictors of Delayed Clearance and Toxicities from High Dose Methotrexate in Patients Receiving Hypercvad Regimen for Treatment of Lymphoid Malignancies. <i>Blood</i> , 2016, 128, 1630-1630.	1.4	0
39	In Vitro Expanded $\alpha\beta$ T Cells Derived from Cord Blood Induce Potent and Specific Cytotoxicity Against Human Acute Myeloid Leukemia Cells. <i>Blood</i> , 2016, 128, 2168-2168.	1.4	0
40	Phase 1/1B trial of the heat shock protein 90 inhibitor NVP-AUY922 as monotherapy or in combination with bortezomib in patients with relapsed or refractory multiple myeloma. <i>Cancer</i> , 2015, 121, 2185-2192.	4.1	51
41	Panobinostat in combination with bortezomib in patients with relapsed or refractory peripheral T-cell lymphoma: an open-label, multicentre phase 2 trial. <i>Lancet Haematology</i> , 2015, 2, e326-e333.	4.6	50
42	Pharmacokinetics and safety of ixazomib plus lenalidomide+dexamethasone in Asian patients with relapsed/refractory myeloma: a phase 1 study. <i>Journal of Hematology and Oncology</i> , 2015, 8, 103.	17.0	37
43	Subcutaneous bortezomib combined with weekly cyclophosphamide and dexamethasone is an efficient and well tolerated regime in newly diagnosed multiple myeloma. <i>British Journal of Haematology</i> , 2015, 169, 754-756.	2.5	12
44	Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial. <i>Lancet Oncology</i> , 2014, 15, 966-974.	10.7	345
45	Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma. <i>Blood</i> , 2014, 123, 4136-4142.	1.4	125
46	Phase 1 Study Of The Novel Pan-Pim Kinase Inhibitor LGH447 In Patients With Relapsed/ Refractory Multiple Myeloma. <i>Blood</i> , 2013, 122, 3186-3186.	1.4	9
47	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Of The Efficacy and Safety Of Siltuximab, An Anti-Interleukin-6 Monoclonal Antibody, In Patients With Multicentric Castleman's Disease. <i>Blood</i> , 2013, 122, 505-505.	1.4	7
48	Essential Thrombocythaemia in Young Adults: Clinical Characteristics and Outcomes – a Single Center Experience. <i>Blood</i> , 2012, 120, 5060-5060.	1.4	0
49	Bortezomib (BTZ) and Panobinostat (PAN) Combination Is Effective in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL) or NK/T-Cell Lymphoma (NKL) and Maintenance Treatment May Be Essential for Sustained Response. <i>Blood</i> , 2012, 120, 3669-3669.	1.4	0
50	Anti-CD22 Immunoconjugate Inotuzumab Ozogamicin (CMC-544) + Rituximab In Relapsed DLBCL Patients Followed by Stem Cell Transplantation: Preliminary Safety and Efficacy. <i>Blood</i> , 2010, 116, 2883-2883.	1.4	2
51	Incorporation of Bortezomib Into Frontline Treatment of Multiple Myeloma According to Risk Stratification Shifts the Most Significant Prognostic Indicator From Cytogenetics to the Quality of Induction Response. <i>Blood</i> , 2010, 116, 3056-3056.	1.4	0
52	Risk of Hepatitis B Virus (HBV) Reactivation and the Role of Anti-Viral Prophylaxis in Multiple Myeloma Patients with HBV Infection in the Era of Novel Therapies.. <i>Blood</i> , 2009, 114, 3882-3882.	1.4	0
53	The M351T BCR-ABL Kinase Mutation Is Uncommon in Asian Patients with Imatinib-Resistant Chronic Myeloid Leukemia: Possible Relationship with Imatinib Plasma Levels.. <i>Blood</i> , 2008, 112, 2122-2122.	1.4	3
54	Dasatinib 140 Mg Once Daily (QD) Demonstrates Equivalent Efficacy and Improved Safety Compared with 70 Mg Twice Daily (BID) in Patients with Chronic Myeloid Leukemia in Blast Phase (CML-BP): 2-Year Data from CA180-035. <i>Blood</i> , 2008, 112, 3226-3226.	1.4	13

#	ARTICLE	IF	CITATIONS
55	Cytokine Induced Killer Cells Are Feasible and Safe for Both Autologous and Allogeneic Applications in Patients with Haematological Malignancies. Blood, 2008, 112, 2917-2917.	1.4	2
56	Studies of Wilms's Tumor (WT1) Gene Expression in Adult Acute Leukemias in Singapore. Biomarker Insights, 2007, 2, 117727190700200.	2.5	1
57	The Leukemias. , 2004, , 581-600.		0